Chimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor Immunity

Optical Imaging of Cellular Immunotherapy against Prostate Cancer

(2018) Sidhartha Tavri et al.   Molecular Imaging

Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor

(2017) K H Chen et al.   LEUKEMIA

Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells

(2017) Waseem Qasim et al.   Science Translational Medicine

Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition

(2016) Jiangtao Ren et al.   CLINICAL CANCER RESEARCH

IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function

(2016) D. A. Vallera et al.   CLINICAL CANCER RESEARCH

Expanded and armed natural killer cells for cancer treatment

(2016) Noriko Shimasaki et al.   CYTOTHERAPY

Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells

(2016) Omkar U. Kawalekar et al.   IMMUNITY

Biology and clinical application of CAR T cells for B cell malignancies

(2016) Marco L. Davila et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

CD19-CAR engineered NK-92 cells are sufficient to overcome NK cell resistance in B-cell malignancies

(2016) Annette Romanski et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape

(2016) Meenakshi Hegde et al.   JOURNAL OF CLINICAL INVESTIGATION

P04.05 The CAR2BRAIN study: a monocentric phase I trial with ErbB2-specific NK-92/5.28.z cells in recurrent glioblastoma

(2016) M. C. Burger et al.   NEURO-ONCOLOGY

Early treatment of HER2-amplified brain tumors with targeted NK-92 cells and focused ultrasound improves survival

(2016) Ryan Alkins et al.   NEURO-ONCOLOGY

Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts

(2016) M Cartellieri et al.   Blood Cancer Journal

Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia

(2016) D. T. Teachey et al.   Cancer Discovery

An NK cell line (haNK) expressing high levels of granzyme and engineered to express the high affinity CD16 allele

(2016) Caroline Jochems et al.   Oncotarget

Novel anti-CD3 chimeric antigen receptor targeting of aggressive T cell malignancies

(2016) Kevin H. Chen et al.   Oncotarget

A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases

(2016) Xilin Chen et al.   Oncotarget

Natural Killer Cells for Immunotherapy – Advantages of the NK-92 Cell Line over Blood NK Cells

(2016) Hans Klingemann et al.   Frontiers in Immunology

Murine allogeneic CD19 CAR T cells harbor potent antileukemic activity but have the potential to mediate lethal GVHD

(2015) E. Jacoby et al.   BLOOD

Disialoganglioside-specific human natural killer cells are effective against drug-resistant neuroblastoma

(2015) Diana Seidel et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

NK-92: an ‘off-the-shelf therapeutic’ for adoptive natural killer cell-based cancer immunotherapy

(2015) Garnet Suck et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Natural Killer Cell Adoptive Transfer Therapy

(2015) Zachary B. Davis et al.   CANCER JOURNAL

Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice

(2015) X. Liu et al.   CANCER RESEARCH

NK-92 cells engineered with anti-CD33 chimeric antigen receptors (CAR) for the treatment of Acute Myeloid Leukemia (AML)

(2015) Sarwish Rafiq et al.   CYTOTHERAPY

Challenges of cancer therapy with natural killer cells

(2015) Hans Klingemann   CYTOTHERAPY

Human Epidermal Growth Factor Receptor 2 (HER2) –Specific Chimeric Antigen Receptor–Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma

(2015) Nabil Ahmed et al.   JOURNAL OF CLINICAL ONCOLOGY

Engineering NK Cells Modified With an EGFRvIII-specific Chimeric Antigen Receptor to Overexpress CXCR4 Improves Immunotherapy of CXCL12/SDF-1α-secreting Glioblastoma

(2015) Nadja Müller et al.   JOURNAL OF IMMUNOTHERAPY

ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma

(2015) Congcong Zhang et al.   JNCI-Journal of the National Cancer Institute

Affinity maturation of T-cell receptor-like antibodies for Wilms tumor 1 peptide greatly enhances therapeutic potential

(2015) Q Zhao et al.   LEUKEMIA

Selective Inhibition of Tumor Growth by Clonal NK Cells Expressing an ErbB2/HER2-Specific Chimeric Antigen Receptor

(2015) Kurt Schönfeld et al.   MOLECULAR THERAPY

ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma

(2015) Congcong Zhang et al.   JNCI-Journal of the National Cancer Institute

Advantages and applications of CAR-expressing natural killer cells

(2015) Wolfgang Glienke et al.   Frontiers in Pharmacology

In Vitro and In Vivo Comparison of Lymphocytes Transduced with a Human CD16 or with a Chimeric Antigen Receptor Reveals Potential Off-Target Interactions due to the IgG2 CH2-CH3 CAR-Spacer

(2015) Béatrice Clémenceau et al.   Journal of Immunology Research

The Application of Natural Killer Cell Immunotherapy for the Treatment of Cancer

(2015) Katayoun Rezvani et al.   Frontiers in Immunology

Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances antitumor activity and survival

(2015) Sabrina Genßler et al.   OncoImmunology

Increased sMICA and TGFβ1levels in HNSCC patients impair NKG2D-dependent functionality of activated NK cells

(2015) Stephan Klöß et al.   OncoImmunology

CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells

(2015) Jianfeng Han et al.   Scientific Reports

Acute GVHD in patients receiving IL-15/4-1BBL activated NK cells following T-cell-depleted stem cell transplantation

(2014) N. N. Shah et al.   BLOOD

Antibody-modified T cells: CARs take the front seat for hematologic malignancies

(2014) M. V. Maus et al.   BLOOD

Current concepts in the diagnosis and management of cytokine release syndrome

(2014) D. W. Lee et al.   BLOOD

Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging Therapies

(2014) Shannon L. Maude et al.   CANCER JOURNAL

Metalloprotease-Mediated Tumor Cell Shedding of B7-H6, the Ligand of the Natural Killer Cell-Activating Receptor NKp30

(2014) E. Schlecker et al.   CANCER RESEARCH

Natural Killer Cells: The Secret Weapon in Dendritic Cell Vaccination Strategies

(2014) Catharina H.M.J. Van Elssen et al.   CLINICAL CANCER RESEARCH

Effect of tumor cells and tumor microenvironment on NK-cell function

(2014) Massimo Vitale et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies

(2014) Saar Gill et al.   IMMUNOLOGICAL REVIEWS

Blocking NK Cell Inhibitory Self-Recognition Promotes Antibody-Dependent Cellular Cytotoxicity in a Model of Anti-Lymphoma Therapy

(2014) Liat Binyamin et al.   JOURNAL OF IMMUNOLOGY

Antigen Sensitivity of CD22-Specific Chimeric TCR Is Modulated by Target Epitope Distance from the Cell Membrane

(2014) S. E. James et al.   JOURNAL OF IMMUNOLOGY

A Think Tank of TINK/TANKs: Tumor-Infiltrating/Tumor-Associated Natural Killer Cells in Tumor Progression and Angiogenesis

(2014) Antonino Bruno et al.   JNCI-Journal of the National Cancer Institute

Specific growth inhibition of ErbB2‑expressing human breast cancer cells by genetically modified NK‑92 cells

(2014) Hui Liu et al.   ONCOLOGY REPORTS

T-Cell and NK-Cell Infiltration into Solid Tumors: A Key Limiting Factor for Efficacious Cancer Immunotherapy

(2014) I. Melero et al.   Cancer Discovery

Targeting CD20+ Aggressive B-cell Non-Hodgkin Lymphoma by Anti-CD20 CAR mRNA-Modified Expanded Natural Killer Cells In Vitro and in NSG Mice

(2014) Y. Chu et al.   Cancer Immunology Research

Are natural killer cells superior CAR drivers?

(2014) Hans Klingemann   OncoImmunology

Soluble ligands for NK cell receptors promote evasion of chronic lymphocytic leukemia cells from NK cell anti-tumor activity

(2013) K. S. Reiners et al.   BLOOD

Focused Ultrasound Delivers Targeted Immune Cells to Metastatic Brain Tumors

(2013) R. Alkins et al.   CANCER RESEARCH

Treatment of patients with advanced cancer with the natural killer cell line NK-92

(2013) Torsten Tonn et al.   CYTOTHERAPY

Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma

(2013) Markus Chmielewski et al.   IMMUNOLOGICAL REVIEWS

Retargeting NK-92 for anti-melanoma activity by a TCR-like single-domain antibody

(2013) Ge Zhang et al.   IMMUNOLOGY AND CELL BIOLOGY

CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma

(2013) J Chu et al.   LEUKEMIA

The human natural killer cytotoxic cell line NK-92, once armed with a murine CD16 receptor, represents a convenient cellular tool for the screening of mouse mAbs according to their ADCC potential

(2013) Béatrice Clémenceau et al.   mAbs

Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells

(2013) Hua Jiang et al.   Molecular Oncology

EGFR-Targeted Granzyme B Expressed in NK Cells Enhances Natural Cytotoxicity and Mediates Specific Killing of Tumor Cells

(2013) Pranav Oberoi et al.   PLoS One

Activating natural cytotoxicity receptors of natural killer cells in cancer and infection

(2013) Joachim Koch et al.   TRENDS IN IMMUNOLOGY

The Basic Principles of Chimeric Antigen Receptor Design

(2013) Michel Sadelain et al.   Cancer Discovery

Bringing natural killer cells to the clinic: ex vivo manipulation

(2013) R. W. Childs et al.   Hematology-American Society of Hematology Education Program

TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy

(2013) Zakaria Grada et al.   Molecular Therapy-Nucleic Acids

The Critical Role of the Tumor Microenvironment in Shaping Natural Killer Cell-Mediated Anti-Tumor Immunity

(2013) Joanna Baginska et al.   Frontiers in Immunology

Role of non-classical MHC class I molecules in cancer immunosuppression

(2013) Grazyna Kochan et al.   OncoImmunology

Arming NK cells with enhanced antitumor activity

(2013) Pranav Oberoi et al.   OncoImmunology

Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity

(2013) Laurent Boissel et al.   OncoImmunology

Clinical Grade Purification and Expansion of NK Cell Products for an Optimized Manufacturing Protocol

(2013) Ulrike Koehl et al.   Frontiers in Oncology

A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR

(2012) H. Torikai et al.   BLOOD

Expression of IL-15 in NK cells results in rapid enrichment and selective cytotoxicity of gene-modified effectors that carry a tumor-specific antigen receptor

(2012) Christiane Sahm et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

The chemoattractant chemerin suppresses melanoma by recruiting natural killer cell antitumor defenses

(2012) Russell K. Pachynski et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Sustained effector function of IL-12/15/18–preactivated NK cells against established tumors

(2012) Jing Ni et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Natural Innate and Adaptive Immunity to Cancer

(2011) Matthew D. Vesely et al.   Annual Review of Immunology

Retargeting NK92 cells using an HLA-A2-restricted, EBNA3C-specific chimeric antigen receptor

(2011) D V Tassev et al.   CANCER GENE THERAPY

Natural Killer Cells are Scarce in Colorectal Carcinoma Tissue Despite High Levels of Chemokines and Cytokines

(2011) N. Halama et al.   CLINICAL CANCER RESEARCH

NK cells engineered to express a GD2-specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal origin

(2011) Ruth Esser et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Transcript signature predicts tissue NK cell content and defines renal cell carcinoma subgroups independent of TNM staging

(2011) Judith Eckl et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

Comparison of mRNA and lentiviral based transfection of natural killer cells with chimeric antigen receptors recognizing lymphoid antigens

(2011) Laurent Boissel et al.   LEUKEMIA & LYMPHOMA

Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy

(2011) Antonio Di Stasi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Distinct Roles for the NK Cell-Activating Receptors in Mediating Interactions with Dendritic Cells and Tumor Cells

(2010) L.-E. Wai et al.   JOURNAL OF IMMUNOLOGY

Tumor Immunoediting by NKp46

(2010) M. Elboim et al.   JOURNAL OF IMMUNOLOGY

Depicting adoptive immunotherapy for prostate cancer in an animal model with magnetic resonance imaging

(2010) Reinhard Meier et al.   MAGNETIC RESONANCE IN MEDICINE

Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2

(2010) Richard A Morgan et al.   MOLECULAR THERAPY

2B4 (CD244) Signaling by Recombinant Antigen-specific Chimeric Receptors Costimulates Natural Killer Cell Activation to Leukemia and Neuroblastoma Cells

(2009) B. Altvater et al.   CLINICAL CANCER RESEARCH

Natural killer cell allorecognition of missing self in allogeneic hematopoietic transplantation: a tool for immunotherapy of leukemia

(2009) Andrea Velardi et al.   CURRENT OPINION IN IMMUNOLOGY

ILT2/HLA-G interaction impairs NK-cell functions through the inhibition of the late but not the early events of the NK-cell activating synapse

(2009) Benoit Favier et al.   FASEB JOURNAL

Natural killer cell-based immunotherapy in cancer: current insights and future prospects

(2009) T. Sutlu et al.   JOURNAL OF INTERNAL MEDICINE

Transfection with mRNA for CD19 specific chimeric antigen receptor restores NK cell mediated killing of CLL cells

(2009) Laurent Boissel et al.   LEUKEMIA RESEARCH

Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo

(2009) Michael C. Milone et al.   MOLECULAR THERAPY

Natural killer cells infiltrating human nonsmall-cell lung cancer are enriched in CD56brightCD16− cells and display an impaired capability to kill tumor cells

(2008) Paolo Carrega et al.   CANCER

Natural Killer Cell Accumulation in Tumors Is Dependent on IFN-  and CXCR3 Ligands

(2008) M. Wendel et al.   CANCER RESEARCH

Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial

(2008) S. Arai et al.   CYTOTHERAPY

NKG2D-Deficient Mice Are Defective in Tumor Surveillance in Models of Spontaneous Malignancy

(2008) Nadia Guerra et al.   IMMUNITY

Up on the tightrope: natural killer cell activation and inhibition

(2008) Lewis L Lanier   NATURE IMMUNOLOGY

Tracking of [18F]FDG-labeled natural killer cells to HER2/neu-positive tumors

(2008) Reinhard Meier et al.   NUCLEAR MEDICINE AND BIOLOGY

Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas

(2008) A. Kruschinski et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA